Lead Product(s) : Gene Therapy
Therapeutic Area : Ophthalmology
Study Phase : Discovery
Sponsor : A*STAR
Deal Size : Undisclosed
Deal Type : Partnership
Ring Partners with A*STAR And SERI for Gene Therapy R&D in Singapore
Details : Wide-ranging A*STAR and SERI partnership will accelerate the development of novel developmental gene therapy candidates in the areas of ophthalmology and oncology.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 05, 2024
Lead Product(s) : Gene Therapy
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery
Sponsor : A*STAR
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Antibody-based Therapy
Therapeutic Area : Ophthalmology
Study Phase : Discovery
Sponsor : GC Biopharma
Deal Size : Undisclosed
Deal Type : Agreement
GC Biopharma And Novelty Nobility Team Up for Geographic Atrophy R&D
Details : GC Biopharma and Novelty Nobility established a partnership to jointly research and develop antibody-based protein therapeutics for GA throughout all stages of the drug development lifecycle.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 28, 2024
Lead Product(s) : Antibody-based Therapy
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery
Sponsor : GC Biopharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : RTx-021
Therapeutic Area : Ophthalmology
Study Phase : Discovery
Sponsor : CIRM
Deal Size : $4.0 million
Deal Type : Funding
Details : The funding will be used to support development of RTx-021, an optogenetic therapy for the treatment of geographic atrophy (GA), the advanced form of age-related macular degeneration (AMD).
Brand Name : RTx-021
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 13, 2023
Lead Product(s) : RTx-021
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery
Sponsor : CIRM
Deal Size : $4.0 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Discovery
Sponsor : Spark Therapeutics, Inc
Deal Size : $216.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, Spark secures exclusive worldwide rights to SpliceBio's proprietary Protein Splicing platform to develop, manufacture, and commercialize a gene therapy targeting an undisclosed inherited retinal disease.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 17, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery
Sponsor : Spark Therapeutics, Inc
Deal Size : $216.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Discovery
Sponsor : AbbVie Inc
Deal Size : $665.0 million
Deal Type : Collaboration
Details : Under the terms of the collaboration, AbbVie's extensive capabilities will be paired with Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability to identify and advance three programs.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $70.0 million
February 23, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery
Sponsor : AbbVie Inc
Deal Size : $665.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Discovery
Sponsor : Everads Therapy
Deal Size : Undisclosed
Deal Type : Collaboration
VivaVision and Everads Collaborate to Develop Durable and Effective Therapies for Retinal Diseases
Details : Under the terms of collaboration agreement, VivaVision and Everads will jointly conduct pre-clinical research activities, in order to identify lead candidates for future clinical development and commercialization.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 06, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery
Sponsor : Everads Therapy
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : AAV-based Gene Therapy
Therapeutic Area : Ophthalmology
Study Phase : Discovery
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,007.5 million
Deal Type : Partnership
Details : The partnership aims to apply Avista’s single-cell adeno-associated virus (AAV) engineering (scAAVengr) platform technology to develop intravitreal AAV capsids matching a capsid profile defined by Roche.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : $7.5 million
July 19, 2022
Lead Product(s) : AAV-based Gene Therapy
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,007.5 million
Deal Type : Partnership